Comparative Pharmacology
Head-to-head clinical analysis: MYSOLINE versus TEGRETOL XR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MYSOLINE versus TEGRETOL XR.
MYSOLINE vs TEGRETOL-XR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Primidone is a barbiturate anticonvulsant that acts by enhancing GABA-A receptor activity and possibly by blocking sodium channels.
Carbamazepine stabilizes inactivated state of voltage-gated sodium channels, thereby inhibiting repetitive neuronal firing and reducing synaptic transmission.
250 mg orally 3 times daily; may increase by 250 mg/day every 3 days; usual maintenance 250 mg 3-4 times daily; maximum daily dose 1500 mg.
200-400 mg orally twice daily; maximum 1200 mg/day for monotherapy, 1600 mg/day for combination therapy.
None Documented
None Documented
Primidone: 5-15 hours (mean 10 hours); PEMA: 10-18 hours; Phenobarbital: 50-120 hours. Steady state achieved in 2-4 weeks due to accumulation of phenobarbital.
Initial: 25-65 hours; chronic dosing: 12-17 hours due to autoinduction. Steady-state reached in 2-4 weeks.
Primidone is excreted primarily in urine; approximately 60-80% as unchanged drug and metabolites (PEMA, phenobarbital), with less than 10% in feces.
Renal: ~72% as unchanged drug and metabolites (primarily glucuronides). Fecal: ~28% via bile (enterohepatic recirculation possible).
Category C
Category C
Anticonvulsant
Anticonvulsant